Start-up builds PET/CT centers
A new company, Morningstar Molecular Imaging, is hatching plans to launch a chain of PET/CT imaging centers across the U.S. The Sarasota, FL, firm will open its first centers in Georgia, Colorado, and Florida later this year. It plans to expand to other
A new company, Morningstar Molecular Imaging, is hatching plans to launch a chain of PET/CT imaging centers across the U.S. The Sarasota, FL, firm will open its first centers in Georgia, Colorado, and Florida later this year. It plans to expand to other states over the next 12 months. The centers will conduct business under the Morningstar Molecular Imaging name and will be jointly owned by Morningstar, local investors, and physicians where appropriate. The business model is based on three strategies: to cluster multiple imaging centers in metropolitan areas so as to establish economies of scale and local branding; provide only PET/CT through the highest performance, LSO-based scanning systems; and tie all its centers together with an IT system that supports referring physician and patient services. Key to the success of this model is a "speed-to-market" approach to ensure that the fledgling company provides service to patients in as many metro areas as soon as possible, according to Ken Manning, vice president of marketing for Morningstar.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
